Biogen Agrees to Pay $22 Million to Resolve Allegations that it Paid Kickbacks Through Two Co-Pay Foundations
BOSTON - Cambridge-based pharmaceutical company Biogen Inc. has agreed to pay $22 million to resolve allegations that it violated the False Claims Act by illegally using two foundations, Chronic Disease Fund (CDF) and The Assistance Fund (TAF), as conduits to pay the Medicare co-pays for patients taking Biogen's multiple sclerosis (MS) drugs, Avonex and Tysabri.
- Date:December 17, 2020
- Agency:U.S. Attorney's Office, District of Massachusetts
- Criminal and Civil Actions